tbuckley/cabot-search huggingface dataset:
Female-to-Male Transmission of HIV
Authors: Harry W. Haverkos
Journal: JAMA (1992)

<h3>To the Editor.</h3> —Padian et al<sup>1</sup>studied 379 heterosexual couples for evidence of human immunodeficiency virus (HIV) transmission and found that male-to-female transmission is much greater than female-to-male. In the single case of female-to-male transmission, the index case had multiple sexual contacts and reported vaginal bleeding during sex, and her regular male partner who seroconverted also reported penile bleeding during sex. Are the results of this study consistent with the results of other such studies? We reviewed the literature searching for HIV serologic studies of heterosexual couples with both male and female index cases.<sup>1-8</sup>Studies were excluded if only female-to-male or male-to-female transmission was studied. We started with all studies referenced in the Padian et al article and reviewed the abstracts of the Seventh International Conference on AIDS. We identified 16 studies meeting the study definition. The designs of the 16 studies were similar. Heterosexual individuals (index cases)
Reply
Authors: Chong‐Gee Teo, Ajay Yesupriya, Man‐Huei Chang, Lyna Zhang
Journal: Hepatology (2016)

Potential conflict of interest: Nothing to report. We appreciate the attention that Weller et al. have given to our report and findings. Weller et al. used an in vitro system based on Huh‐7.5 cells silenced for endogenous apolipoprotein E (apoE) protein expression to investigate if genetic variants of the APOE gene (ϵ2, ϵ3, and ϵ4), when ectopically expressed, influence the production of intracellular hepatitis E virus (HEV) RNA and the expression of HEV open reading frame 2 (ORF2) protein after the cells were transfected with an HEV genotype 3 replicon. Finding that HEV RNA and ORF2 protein production were not affected regardless of which isoforms were expressed, they concluded that APOE polymorphisms do not affect HEV RNA replication and virus production. HEV RNA quantification was applied by Weller et al. as an index of viral replication, and ORF2 protein quantification was used as a marker of the extent of viral particle assembly. However, HEV RNA measurement shows replication of the viral genome, not productive viral replication. Furthermore, measurement of the ORF2 protein, per se, is inadequate to indicate virion assembly; and other means of verifying if assembly has taken place are needed.1 We also note that although the data depicted in Fig. 1C,D show a trend in the reduction in production levels of HEV RNA and ORF2, respectively, when HuH‐7.5 cells were incubated in the presence of ribavirin, no formal statistics were applied to analyze the trend. The ranges for the ribavirin‐associated data points were wide. In addition, genotypes 1 and 3 were reported by HEV surveillance as principal infecting genotypes in the United States2; Weller et al. only used genotype 3 in their experiments. Weller et al. also concluded that their data do not support the findings of our study,3 suggesting that APOE ϵ3 and APOE ϵ4 were associated with protection against HEV infection in non‐Hispanic blacks but not in non‐Hispanic whites or Mexican Americans. What we conducted was a population‐based genetic epidemiologic association study following up on previously reported epidemiologic data showing the anti‐HEV seropositivity rate among non‐Hispanic blacks to be lower than that among the other two racial/ethnic groups.4 We identified the host genetic factor associated with the lower seropositivity to be APOE or genes that are in linkage disequilibrium with APOE. Assuming that APOE is a gene that confers protection against HEV infection, we proffered various mechanisms by which the apoE protein can exert such protection: (1) HEV using the same hepatocyte entry mediators as those of apoE, (2) the incorporation of apoE in the HEV envelope, and (3) apoE modulating the immune response against HEV. The role of apoE as having the capability to affect HEV replication was not considered, as Weller et al. had.
Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC)
Authors: R. Glynne-Jones, D. Sebag-Montefiore, L. Samuel, S. Falk, T. Maughan, A. McDonald
Journal: Journal of Clinical Oncology (2005)

3527 Background: CAP, an oral fluoropyrimidine preferentially activated to 5-FU in tumors by the enzyme thymidine phosphorylase (TP), has superior antitumor activity and favorable safety compared with bolus i.v. 5-FU/LV in pts with metastatic colorectal cancer (MCRC). OX plus 5-FU/LV further improves outcomes in MCRC. Preclinical xenograft models show that RT and OX both upregulate tumor TP vs normal tissue. The aim of this study was firstly to determine the recommended dose of pre-operative CAP in combination with OX and pelvic RT in pts with LARC, and secondly to assess the efficacy and safety of this regimen. Methods: Pts with primary unresectable LARC received CAP (500, 650, 825mg/m2 twice daily) 7 days/week during RT, OX 130mg/m2, days 1 and 29 and RT (25 fractions of 1.8Gy; 45Gy total over 25 days). After identifying the maximum tolerated dose (MTD) of CAP, the study continued into phase II. Results: 94 patients were enrolled in the study; six in each phase I cohort, and another 76 in phase II. Median age is 61 years (24–77); most pts are male (75%), and Caucasian (97%). Dose-limiting toxicities (DLTs) occurred in 2/6 pts receiving CAP 825mg/m2 (grade 3 diarrhea and moist desquamation), establishing the recommended dose of CAP as 650mg/m2 twice daily in the phase II. To date, 87 pts have undergone surgery. Complete pathologic responses occurred in 15 (18%) of pts and a further 20 classified at Tmic (total 45%), 16 (20%) were downstaged to pT1T2N0 and 70/80 (87%) had tumor-free circumferential resection margins (pathological details available on 80 pts). Among 87 pts evaluable for safety, the most common treatment-related adverse events (AEs) were paresthesia (51%), diarrhea (48%), nausea (41%), and lethargy (31%). In phase II 9/87 pts had G3–4 diarrhea and 2/87 had G3–4 lethargy. Conclusions: The recommended dose of neoadjuvant CAP is 650mg/m2 twice daily with OX 130mg/m2 (days 1 and 29) and pelvic RT. The regimen is well tolerated and shows very high rates of histopathologically confirmed curative resection. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Hoffmann-La Roche, sanofi-aventis Hoffmann-La Roche, sanofi-aventis Hoffmann-La Roche, sanofi-aventis
The origin and role of innate lymphoid cells in the lung
Authors: Deng-Ming Lai, Qiang Shu, Jie Fan
Journal: Military Medical Research (2016)

Innate lymphoid cells (ILCs), a newly identified member of the lymphoid population, play a critical role in the transition from innate to adaptive immunity in host defense. ILCs are important in mucosal barrier immunity, tissue homeostasis, and immune regulation throughout the body. Significant alterations in ILC responses in lung diseases have been observed and reported. Emerging evidence has shown that ILCs are importantly involved in the pathogenesis and development of a variety of lung diseases, i.e., helminth infections, allergic airway inflammation, and airway hyper-responsiveness. However, as a tissue-resident cell population, the role of ILCs in the lung remains poorly characterized. In this review, we discuss the role of ILCs in lung diseases, the mechanisms underlying the ILC-mediated regulation of immunity, and the therapeutic potential of modulating ILC responses.
Identiﬁcation Of a Novel Small-Molecule TNFα Inhibitor With Activity Against Inflammation In a Hepatitis Mouse Model
Authors: Li Ma, Haiyan Gong, Haiyan Zhu, Pei Su, Shannan Cao, Peng Liu, Jianfeng Yao, Ming-Zhe Han, Hongbo R. Luo, Fei Wang, Jiaxi Zhou, Yuanfu Xu
Journal: Blood (2013)
Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer
Authors: Kari E. Hacker, Shitanshu Uppal, Carolyn Johnston
Journal: Journal of the National Comprehensive Cancer Network (2016)

Borderline ovarian tumors (BOTs) are less common than epithelial ovarian cancers (EOCs). Low-grade EOCs (LG-EOCs) occur even less frequently than BOTs. After primary therapy, recurrence rates of BOTs and LG-EOCs are significantly lower and the stage-adjusted survival is higher than for high-grade EOCs. Thus, determining the best management in terms of traditional ovarian cancer staging and debulking procedures is more challenging and has been recently brought to question. This article reviews the particulars of BOTs and LG-EOCs, their similarities and differences, and how they are best managed and treated, and emphasizes the major role of surgery and the controversial role of chemotherapy. Because these tumors disproportionately affect younger women, this review addresses ovarian preservation in circumstances when fertility or hormonal preservation is desired.
Abstract 13565: Patterns of Newly Detected Atrial Fibrillation and Antithrombotic Treatment in GLORIA-AF Phase II
Authors: Jonathan L Halperin, Menno V Huisman, Hans-Christoph Diener, Sergio J Dubner, Changsheng Ma, Kenneth J Rothman, Nils Schoof, Amelie Elsaesser, Miney Paquette, Dorothee B Bartels, Christine Teutsch, Gregory H Lip
Journal: Circulation (2015)

Purpose/Background: Anticoagulation with Vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) is recommended for patients with atrial fibrillation (AF) and additional risk factors for stroke, regardless of the pattern of AF. Using an inception cohort design, GLORIA-AF collected data on antithrombotic therapy choices for patients with newly identified AF at risk of stroke in the course of routine care. Methods: Phase II began after the first NOAC became available for stroke prevention in AF and baseline data were recorded from November 2011 through December 2014 in 44 countries worldwide. To reduce selection bias, patients were recruited consecutively, irrespective of antithrombotic therapy received. Antithrombotic treatment is presented in relation to CHA 2 DS 2 VASc scores and the pattern of AF. Results: In phase II of GLORIA-AF, 15,092 patients with a recent diagnosis of AF and CHA 2 DS 2 VASc scores ≥ 1 were enrolled. Median age was 71 years and 39.1% were ≥ 75 years old; 45.5% were female, 74.6% had a history of hypertension, 23.1% diabetes mellitus and 86.1% had CHA 2 DS 2 VASc scores ≥ 2. AF was classified as paroxysmal in 53.4% (n = 8052), persistent in 35.5% (n = 5362) and permanent in 11.1% (n = 1678) of patients. Relationships of initial antithrombotic therapy to AF pattern and stroke risk are shown in the figure below and further data on regional differences will be presented. Conclusion: Initial antithrombotic therapy diverged from guideline recommendations. Patients with paroxysmal AF were less often anticoagulated than those with persistent or permanent AF, and nearly 22% of patients with paroxysmal AF at high stroke risk were untreated, or given aspirin or other antiplatelet therapy alone.
The Gene Expression Signatures (GEP) of Whole Bone Marrow Biopsies (Bx) from Patients with Multiple Myeloma (MM) in Remission Reflect Disease Risk and Therapy.
Authors: Fenghuang Zhan, Yongsheng Huang, Rudy Van Hemert, Owen Stephens, Bart Barlogie, John Shaughnessy
Journal: Blood (2005)
Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation
Authors: A N McCracken, R J McMonigle, J Tessier, R Fransson, M S Perryman, B Chen, A Keebaugh, E Selwan, S A Barr, S M Kim, S G Roy, G Liu, D Fallegger, L Sernissi, C Brandt, N Moitessier, A J Snider, S Clare, M Müschen, A Huwiler, M T Kleinman, S Hanessian, A L Edinger
Journal: Leukemia (2016)
RCHOP-21 Vs. RCHOP-14 for the Treatment of Newly Diagnosed Diffuse Large B Cell Lymphoma: A Prospective Randomized Phase III Clinical Trial from Cswog
Authors: Tongyu Lin, He Huang, Xueying Li, Chengcheng Guo, Huangming Hong, Xiaohong Fu, Xiaoting Lin, Xiaojie Fang, Zhao Wang, Zhongjun Xia
Journal: Blood (2015)
Laryngeal Dysfunction: Assessment and Management for the Clinician
Authors: James H. Hull, Vibeke Backer, Peter G. Gibson, Stephen J. Fowler
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<Laryngeal Development: Di...The Concept of Clinical L...Approach to AssessmentApproach to ManagementConclusionsReferencesCITING ARTICLES
Exposure to Air Pollutants and Myocardial Infarction Risk—Reply
Authors: Hazrije Mustafić, Xavier Jouven, Patricia Jabre
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Authors: Stuart J. Connolly, Truman J. Milling, John W. Eikelboom, C. Michael Gibson, John T. Curnutte, Alex Gold, Michele D. Bronson, Genmin Lu, Pamela B. Conley, Peter Verhamme, Jeannot Schmidt, Saskia Middeldorp, Alexander T. Cohen, Jan Beyer-Westendorf, Pierre Albaladejo, Jose Lopez-Sendon, Shelly Goodman, Janet Leeds, Brian L. Wiens, Deborah M. Siegal, Elena Zotova, Brandi Meeks, Juliet Nakamya, W. Ting Lim, Mark Crowther
Journal: New England Journal of Medicine (2016)

Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers.
Further Misanalysis of Urinalysis—Reply
Authors: Kathryn B. Holroyd, Alexander Rittenberg, Amit Pahwa
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Cytogenetics and Outcome Of Infants With Acute Lymphoblastic Leukemia and Absence Of MLL Rearrangements
Authors: Christine J Harrison, Anthony V. Moorman, Paola de Lorenzo, Rob Pieters, Zoann E. Dreyer, Nyla A. Heerema, Andrew J. Carroll, Stephen P. Hunger, Richard C. Harvey, Cheryl L. Willman, Meenakshi Devidas, Maria Grazia Valsecchi
Journal: Blood (2013)
A prospective feasibility study of clofarabine (CLO) cytoreduction prior to allogeneic stem cell transplant (HCT) conditioning for refractory leukemia and MDS.
Authors: F. L. Locke, A. S. Artz, L. A. Godley, O. Odenike, R. A. Larson, K. Van Besien, W. Stock
Journal: Journal of Clinical Oncology (2010)

6537 Background: Patients with active disease at HCT conditioning fare poorly and disease burden correlates with outcome. Methods: We present preliminary results of a prospective single institution feasibility study of CLO 30 mg/m2 iv daily for 5 consecutive days as a pre-HCT cytoreductive agent followed by HCT conditioning 15-21 days after initiation of CLO. All patients (pts) had active disease. At analysis 17 pts were enrolled and evaluable; 8 AML, 5 MDS, 2 ALL, and 2 CML; median age was 48 (range 23-65); donors were 7 matched related, 9 matched unrelated, and 1 cord + haplo supplemented adult. The conditioning regimens were investigator determined (5 ablative, 12 reduced intensity), all but 2 contained alemtuzumab. Results: CLO therapy was well tolerated with skin, renal, liver, and infectious toxicity incidence (CTCAE v.3) prior to HCT day 0 as follows: 12% grade (gr.) 2 hand- foot syndrome; 29% gr. 1 and 6% gr. 3 SGOT elevation; 41% gr. 1-2 and 6% gr. 3 bilirubin elevation; 41% neutropenic fever, with 29% having fever and an identified infection. All renal/liver toxicities attributed to CLO resolved by HCT day 10. The primary endpoint was effective cytoreduction, defined as a nadir (12 days after CLO initiation) BM cellularity < 20% and BM blast% < 10%. This was achieved in 6/17 (35%) pts. Median BM cellularity was 37% pre- and 12.5% post-CLO. Median BM blast% was 11% pre and 6% post. 17/17 (100%) pts proceeded to HCT infusion (median of 21 days, range 17-36) after CLO initiation. With median follow-up 3.4 months after HCT for survivors (range 1-21), one year OS = 46% by Kaplan-Meier estimate. 8 pts are alive in remission, 2 are alive following relapse. 7/17 (41%) relapsed at a median of 5.7 months (range 1-11.8). TRM is 1/17, with death at 10.3 months of gVH complications. No VOD occurred. Pts effectively cytoreduced had increased PFS, 11.8 vs 5.7 months (p = 0.04, HR = 4.1, 95%CI = 1.1 to 22.1), and improved OS (p = 0.07, HR = 5.3, 95%CI = 0.9 to 26.9) by logrank test, with median OS not yet reached for cytoreduced patients. Conclusions: Clofarabine followed by immediate HCT is feasible with acceptable toxicity. Achievement of cytoreduction may predict for outcome following HCT. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genzyme Genzyme Genzyme
Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.
Authors: Jia Ruan, Morton Coleman, Richard R. Furman, Patricia Glynn, Maureen Joyce, Jamie Ketas, Ken Cheung, Sarah Church, Tsiporah Shore, Eric Feldman, Sarah Rutherford, Elizabeth Hyjek, Amy Chadburn, Shahin Rafii, John P. Leonard
Journal: Blood (2006)
Response to Comment on Beltrand et al. Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations. Diabetes Care 2015;38:2033–2041
Authors: Jacques Beltrand, Michel Polak
Journal: Diabetes Care (2016)

We would like to respond to the comment made by Beltrand et al. (1). In our study (2), we hypothesized that a successful switch from insulin to sulfonylurea therapy in patients with neonatal diabetes owing to KATP channel mutations would improve neurodevelopmental parameters. It was a prospective single-center cohort study of patients switched from insulin to sulfonylurea therapy. The inclusion criterion was neonatal diabetes owing to a mutation in the KCNJ11 or ABCC8 gene. We did not anticipate the neuropsychological changes …
Exploiting CD22 on antigen-specific B cells to prevent allergy to the major peanut allergen Ara h 2
Authors: Kelly A. Orgel, Shiteng Duan, Benjamin L. Wright, Soheila J. Maleki, John C. Wolf, Brian P. Vickery, A. Wesley Burks, James C. Paulson, Mike D. Kulis, Matthew S. Macauley
Journal: Journal of Allergy and Clinical Immunology (2016)
What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study.
Authors: B. K. Bennett, D. Goldstein, F. M. Boyle, P. L. De Souza, N. Wilcken, M. Friedlander, I. Hickie, E. Scott, N. Rogers, A. R. Lloyd
Journal: Journal of Clinical Oncology (2010)

605 Background: Daytime fatigue and poor quality sleep are more common in patients with cancer than healthy populations. Self-reported sleep disturbance is significantly associated with fatigue severity in post-cancer fatigue (PCF). In women treated for breast cancer, early menopause-associated vasomotor symptoms may trigger sleep disturbance. The
Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis
Authors: Ju Dong Yang, Manal F. Abdelmalek, Cynthia D. Guy, Ryan M. Gill, Joel E. Lavine, Katherine Yates, Jagpal Klair, Norah A. Terrault, Jeanne M. Clark, Aynur Unalp-Arida, Anna Mae Diehl, Ayako Suzuki, Srinivasan Dasarathy, Jaividhya Dasarathy, Carol Hawkins, Arthur J. McCullough, Srinivasan Dasarathy, Arthur J. McCullough, Mangesh Pagadala, Rish Pai, Ruth Sargent, Manal F. Abdelmalek, Mustafa Bashir, Stephanie Buie, Anna Mae Diehl, Cynthia Guy, Christopher Kigongo, Yi-Ping Pan, Dawn Piercy, Naga Chalasani, Oscar W. Cummings, Samer Gawrieh, Marwan Ghabril, Smitha Marri, Linda Ragozzino, Kumar Sandrasegaran, Raj Vuppalanchi, Debra King, Pat Osmack, Joan Siegner, Susan Stewart, Brent A. Neuschwander-Tetri, Susan Torretta, Brandon Ang, Cynthia Behling, Archana Bhatt, Rohit Loomba, Michael Middleton, Heather Patton, Claude Sirlin, Bradley Aouizerat, Nathan M. Bass, Danielle Brandman, Linda D. Ferrell, Ryan Gill, Bilal Hameed, Claudia Ramos, Norah Terrault, Ashley Ungermann, Pradeep Atla, Brandon Croft, Rebekah Garcia, Sonia Garcia, Muhammad Sheikh, Mandeep Singh, Sherry Boyett, Laura Carucci, Melissa J. Contos, Kenneth Kraft, Velimir A.C. Luketic, Puneet Puri, Arun J. Sanyal, Jolene Schlosser, Mohhamad S. Siddiqui, Ben Wolford, Sarah Ackermann, Shannon Cooney, David Coy, Katie Gelinas, Kris V. Kowdley, Maximillian Lee, Tracey Pierce, Jody Mooney, James E. Nelson, Cheryl Shaw, Asma Siddique, Chia Wang, Elizabeth M. Brunt, Kathryn Fowler, David E. Kleiner, Gilman D. Grave, Edward C. Doo, Jay H. Hoofnagle, Patricia R. Robuck, Averell Sherker, Patricia Belt, Jeanne M. Clark, Michele Donithan, Erin Hallinan, Milana Isaacson, Kevin P. May, Laura Miriel, Alice Sternberg, James Tonascia, Aynur Ünalp-Arida, Mark Van Natta, Ivana Vaughn, Laura Wilson, Katherine Yates
Journal: Clinical Gastroenterology and Hepatology (2016)